Brain

The International Myeloma Foundation and Black Swan Research Initiative® Announce the Release of New iStopMM Cohort Study: A Multivariable Prediction Model for Bone Marrow Sampling on Individuals with MGUS

STUDIO CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) and Black Swan Research Initiative® (BSRI)…

3 months ago

Horizon Technology Finance Provides First Quarter 2024 Portfolio Update

- HRZN Originates $33.5 Million of New Loans in Q1 - - HRZN Ends Quarter with Committed Backlog of $168…

3 months ago

New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital

Lack of early symptom improvement is not predictive of final responder statusMALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics,…

3 months ago

Eli Lilly’s and AstraZeneca’s Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board

STOCKHOLM, SWEDEN / ACCESSWIRE / April 10, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB ("AlzeCure" or "the Company"), a…

3 months ago

MyndTec Brain Activity Technology Licensed from UHN Awarded U.S. Patent

Mississauga, Ontario--(Newsfile Corp. - April 9, 2024) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), an emerging player in…

3 months ago

Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

The new Gen-3 HALO™ Clarity 15 milliamp (mA) The new Gen-3 HALO™ Clarity 15 milliamp (mA) The new Gen-3 HALO™…

3 months ago

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a…

3 months ago

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast…

3 months ago

FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Toronto, Ontario--(Newsfile Corp. - April 7, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or…

3 months ago